World Journal of Oncology Has Gained an Impact Factor of 5.2 by Journal Citation Reports
Notice bibliographique
Résumé
World Journal of Oncology has been publishing original contributions describing basic research and clinical investigation that cover cellular, molecular, prevention, diagnosis, therapy, translational oncology, and prognosis aspects of cancer.All publications have been indexed in the National Library of Medicine's PubMed database since 2010, including 50 from 2022.Its robust collection of publications demonstrates its commitment to advancing the scientific understanding and clinical management of cancer.Journal Citation Reports (JCR), which is integrated with the Web of Science, is published annually by Clarivate, and provides journal impact factors (IFs) that rank academic journals in the natural and social sciences from all over the world.The 2022 version was published at the end of June 2023, and included 21,522 journals from 112 countries, where 13,668 were science journals and the rest included social science and arts and humanities journals.Data provided in the 2022 version prove to be an invaluable resource for researchers, librarians, and academic institutions as they make informed decisions about journal subscriptions and research dissemination.IF is calculated by dividing the number of citations for articles published in the Web of Science indexed journals in the previous 2 years during the index year by number of articles published in our journal in previous 2 years (Fig. 1).This year, World Journal of Oncology gained its first IF of 5.2.This means that the articles published during 2020 or 2021 in World Journal of Oncology have been cited 5.2 times on aver-age.This ranks World Journal of Oncology 47 of 317 journals in Oncology category of JCR.This is quite a triumph given that we are among the top prestigious journals, such as Cancer Science (IF = 5.7),American Journal of Cancer Research (IF = 5.3), International Journal of Oncology (IF = 5.2), Cancers (IF = 5.2), Molecular Cancer Research (IF = 5.2) and Chinese Journal of Cancer Research (IF = 5.1).In fact, World Journal of Oncology was ranked higher than some leading journals of the field such as Frontiers in Oncology, Breast Cancer, Cancer Medicine, JCO Oncology Practice, EJSO, BMC Cancer, Annals of Surgical Oncology, Breast Cancer Research and Treatment, and Oncology.As mentioned in our previous editorial article [1], World Journal of Oncology promotes articles from around the world to address diversity in oncology.To this end, we investigated the top 10 countries that contributed the most papers to the World Journal of Oncology in the most recent 3 years which were: USA, Japan, China, Mexico, Israel, India, Nepal, Nigeria, Canada, France, Germany, Greece, Indonesia, Italy, and Saudi Arabia (seven countries tied in nineth place), in that order.Among the most cited papers published in World Journal of Oncology during the last 2 years, one-third were on "global oncology".These include reports from developing countries including a review of personalized medicine in the developing world [2], reports on breast cancer in Jamaica [3], in Nigeria [4], and in Mexico [5], on oral cancer in the Gulf Cooperation Council Countries [6], on non-Hodgkin lymphoma [7], and on ovarian cancer [8] in Mexico.The remaining two-thirds were: four review articles on the epidemiology of renal cell carcinoma [9], management of melanoma [10], metastatic renal cell carcinoma [11], and rare urogenital cancers [12]; five original articles: the Surveillance Epidemiology and End Results (SEER) database analysis of esophageal cancer [13], sarcopenia and visceral adiposity on effect of immunotherapy [14] and as a biomarker [15] in non-small cell lung cancer, effect of rapamycin on the radio-sensitivity [16], and programmed death-ligand 1 receptor (PD-L1) expression as a prognosticator of triple negative breast cancer [17]; and four case reports: cervical cancer with OHVIRA (obstructed hemivagina and ipsilateral renal anomaly) syndrome [18], metformin on breast cancer with diabetes [19], scalp leiomyosarcoma management [20] and the lung cancer community [21] during coronavirus disease 2019 (COVID-19) pandemic.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,016 | 0,064 |
| Méta-épidémiologie (sens strict) | 0,004 | 0,001 |
| Méta-épidémiologie (sens large) | 0,004 | 0,002 |
| Bibliométrie | 0,020 | 0,009 |
| Études des sciences et des technologies | 0,003 | 0,003 |
| Communication savante | 0,018 | 0,006 |
| Science ouverte | 0,003 | 0,003 |
| Intégrité de la recherche | 0,009 | 0,012 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,039 | 0,030 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».